论文部分内容阅读
目的:观察黄芪注射液联合抗结核药治疗肺结核的临床疗效。方法:将120例肺结核患者分为对照组和观察组各60例,对照组患者采用抗结核西药进行治疗,观察组患者在西药的基础上加用黄芪注射液静脉滴注治疗。比较两组患者的痰菌转阴率和空洞闭合情况。结果:经过治疗,对照组患者第一季度末痰菌转阴率为71.67%,观察组患者为93.33%;对照组患者空洞闭合率为60.00%,观察组为80.00%。两组患者临床疗效比较差异具有统计学意义(P<0.05)。结论:采用黄芪注射液联合抗结核西药治疗肺结核可有效改善临床治疗效果,提高痰菌转阴率,减少空洞数量,值得临床推广应用。
Objective: To observe the clinical efficacy of Astragalus injection combined with anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Methods: 120 cases of tuberculosis patients were divided into the control group and the observation group of 60 cases, the control group of patients with anti-tuberculosis drugs for the treatment of patients in the observation group on the basis of western medicine plus Astragalus injection intravenous infusion. The sputum negative rate and void closure in two groups were compared. Results: After treatment, the rate of sputum negative conversion in the control group was 71.67% at the end of the first quarter and 93.33% in the observation group. The void closure rate was 60.00% in the control group and 80.00% in the observation group. The difference between the two groups was statistically significant (P <0.05). Conclusion: Astragalus injection combined with anti-tuberculosis western medicine can effectively improve the therapeutic effect of pulmonary tuberculosis, improve the rate of sputum negative conversion and reduce the number of cavities, which is worthy of clinical application.